Los Angeles, CA -- (SBWIRE) -- 06/01/2006 -- Results of
the Alcon FDA Custom Cornea wavefront based LASIK clinical trial
for farsighted astigmatism show that wavefront-based LASIK provides
better results in terms of uncorrected visual acuity and contrast
sensitivity and reduced the induction of higher order aberrations
compared to conventional LASIK with the Alcon system.
The study was presented in March at the meeting of the American
Society of Cataract and Refractive Surgeons in San Francisco by
James Salz, MD.
“Just as in Alcon wavefront based CustomCornea LASIK for nearsightedness,
the results in the farsighted eyes showed superior outcomes,” stated
Dr. Salz. “A higher percentage of patients achieved uncorrected
vision of 20/20 and 20/40. Visual quality was improved as evidenced
by better contrast sensitivity and less increase in higher order
aberrations when compared to conventional LASIK.”
LASIK is a popular form of laser eye surgery uses a combination
of automated lamellar keratoplasty (ALK) using a microkeratome (FDA
approved) to create a “flap” and the excimer laser (FDA approved)
to reshape the cornea (“zap”). LASIK is the most commonly performed
laser eye procedure worldwide.
Laser eye surgery was first approved by the FDA in 1996 and the
procedure has undergone multiple refinements since the original
approval including flap creation with a laser instead of a blade
and customized wavefront based treatments which improve the chances
of obtaining 20/20 vision or better and provide better quality vision
with a lower probability of any side effects.
